Clinical trials: Non-metastatic Prostate Cancer
Adenocarcinoma of the Prostate
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
This single arm, multicenter, open-label, Phase II study will enroll chemotherapy-naive participants with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2).
- Trial name
- NCT00520481
- Testing
- IMC-A12 (Cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer Non-Metastatic, Castration-Resistant
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
- Trial name
- ARAMIS (NCT02200614)
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 404 sites in United States, Argentina and 34 more
- Volunteers
- 1,509 people
- Sponsor
- Bayer
Metastatic Castrate Resistant Prostate Cancer
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
The purpose of this study is to confirm that tasquinimod used as maintenance therapy is active and tolerable in patients with metastatic castrate-resistant prostate cancer not progressing after a first chemotherapy with docetaxel.
- Trial name
- NCT01732549
- Testing
- Tasquinimod
- Where
- 58 sites in Belgium, Czechia and 9 more
- Volunteers
- 144 people
- Sponsor
- Ipsen
Prostate Adenocarcinoma
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate cancer (PC) remains the most-common non-cutaneous cancer diagnosed in American males, accounting for an estimated 174,560 estimated new cases and 31,620 estimated deaths in 2019.
- Trial name
- NCT02624518
- Testing
- 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal suppression and demonstrate increased bone turnover…
- Trial name
- NCT00859027
- Testing
- risedronate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UConn Health
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Prostate Cancer
Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer
This is a Phase II, single center study measuring the pharmacokinetic parameters of NDGA administration and assessing the proportion of patients who experience a 50% decline in PSA.
- Trial name
- NCT00678015
- Testing
- Nordihydroguaiaretic Acid (NDGA)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Non-metastatic Prostate Cancer
PROState Pathway Embedded Comparative Trial
The proposal will explore a trial design called the cohort-multiple RCT (cmRCT) or as it has been recently coined, the Trials WithIn Cohorts (TWICS) design.
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP3-PROSPECT (NCT04400656)
- Where
- 3 sites in United Kingdom
- Volunteers
- 139 people
- Sponsor
- Imperial College London
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Background: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor
- Trial name
- NCT03493945
- Testing
- M7824, N-803, MVA-BN-Brachyury
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…
- Trial name
- POSEIDON (NCT01313273)
- Testing
- Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ipsen
Prostate Cancer
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from growing in patients with rising prostate-specific…
- Trial name
- NCT00551525
- Testing
- Radiotherapy, Samarium 153
- Where
- 29 sites in United States
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Non-metastatic Prostate Cancer
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
Men diagnosed with significant cancer confined to the prostate currently undergo radical therapy directed to the whole prostate (radiotherapy or prostatectomy).
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP4-CHRONOS (NCT04049747)
- Testing
- Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy], Focal therapy, Focal therapy after Finasteride 5Mg tablets for 12 weeks
- Where
- 10 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer.
- Trial name
- NCT02903160
- Testing
- Abiraterone acetate, Prednisone, Radium-223 dichloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate…
- Trial name
- NCT00670046
- Testing
- valproic acid, standard of care follow-up
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
A Study of Olaparib and Durvalumab in Prostate Cancer
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
- Trial name
- NCT03810105
- Testing
- Olaparib, Durvalumab
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center